Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington, [D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response	: 0.5							

					or Sec	ction 3	0(h) of the Ir	nvestme	nt Cor	npany Act of	f 1940						
Name and Address of Reporting Person* Happel David				2. Issuer Name and Ticker or Trading Symbol Sagimet Biosciences Inc. [SGMT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Trapper David											X Dir	ector	10	% Ov	vner		
(Last)	(Fir	rst) (N	Middle)		3. Date of Earliest Transaction (Month/Day/Year)							Officer (give title pelow)		Other (specify below)			
SAGIMI	SAGIMET BIOSCIENCES INC.				12/01/2023								President & CEO				
155 BOVET RD., SUITE 303				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)													,	m filed by Or	ne Reporting	Perso	on
SAN MA	ATEO CA	A 9	4402											m filed by Mo son	ore than One	Repo	orting
(City)	(St	ate) (Ž	Zip)		Rule 10b5-1(c) Transaction Indication												
					C	heck thatisfy th	nis box to indic ne affirmative	cate that a	a trans condition	action was manns of Rule 10	ade pursua 0b5-1(c). S	ant to a ee Instr	contract, in uction 10.	struction or writ	tten plan that	s inter	nded to
		Table	I - Nor	n-Deriva	tive S	ecur	rities Acq	uired,	Dis	posed of	or Bei	nefici	ally Ow	ned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			y/Year) Execution if any		ution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (ADisposed Of (D) (Instr. 3, 5)			nd Secu Bend Own	nount of rities ificially ed Following orted	6. Ownersl Form: Dire (D) or Indir (I) (Instr. 4)	ect	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price	Tran	saction(s) r. 3 and 4)			(Instr. 4)	
Series A Common Stock 12/07/2			2023		P 1,600 A \$4.1 ⁽¹⁾ 627,100		527,100	D									
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deel Execution if any (Month/I		4. Transac Code (li 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	6. Date Expirati (Month/	on Da		7. Title an Amount of Securitie Underlyin Derivativ Security 3 and 4)	of s ng e	8. Price of Derivative Security (Instr. 5)		Owne Form: Direct or Ind (I) (Ins	(D) irect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from \$4.02 per share to \$4.16 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price.

Exercisable

(D)

and 5)

(A)

/s/ Elizabeth Rozek, Attorney12/08/2023 in-Fact

Amount or Number

of Shares

Title

Expiration Date

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.